WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 205965

CAS#: 114517-02-1

Description: Fosquidone is a water-soluble pentacyclic pyrolloquinone analogue of mitoquidone with potential antineoplastic activity. Currently, the mechansim of action of fosquidone is unknown. In vitro studies indicate that this agent does not bind to DNA or inhibit topoisomerases. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Chemical Structure

CAS# 114517-02-1

Theoretical Analysis

MedKoo Cat#: 205965
Name: Fosquidone
CAS#: 114517-02-1
Chemical Formula: C28H22NO6P
Exact Mass: 499.11847
Molecular Weight: 499.451
Elemental Analysis: C, 67.33; H, 4.44; N, 2.80; O, 19.22; P, 6.20

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2021-03-06. Prices are subject to change without notice.

Fosquidone is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Synonym: Fosquidone; GR63178A

IUPAC/Chemical Name: benzyl (14-methyl-8,13-dioxo-5,8,13,14-tetrahydrobenzo[5,6]isoindolo[2,1-b]isoquinolin-9-yl) hydrogen phosphate


InChi Code: InChI=1S/C28H22NO6P/c1-17-20-11-6-5-10-19(20)14-29-15-22-25(26(17)29)27(30)21-12-7-13-23(24(21)28(22)31)35-36(32,33)34-16-18-8-3-2-4-9-18/h2-13,15,17H,14,16H2,1H3,(H,32,33)

SMILES Code: O=P(OC1=C(C2=CC=C1)C(C3=CN4CC5=C(C=CC=C5)C(C)C4=C3C2=O)=O)(OCC6=CC=CC=C6)O

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 499.451 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

 1: Kaye SB, Wanders J, Clavel M, Verweij J, Piccart MJ, Smyth JF, Ten Bokkel Huinink WW, Wagener DJ, Judson IR, Cavalli F. Phase II trials of fosquidone (GR63178A) in carcinoma of the breast, head and neck, ovary and melanoma. Ann Oncol. 1992 May;3(5):406-8. PubMed PMID: 1616895.

2: Planting AS, van der Burg ME, Stoter G, Beranek P, Verweij J. Phase I study of intravenous fosquidone (GR63178A-NSC D611615) using a three times a week schedule. Clin Oncol (R Coll Radiol). 1992 May;4(3):171-3. PubMed PMID: 1586634.

3: Kaye SB, Brampton M, Harper P, Smyth J, Kerr DJ, Gore M, Green JA, Gilby E, Crawford SM, Rustin GJ. Phase II trials of fosquidone, (GR63178A), in colorectal, renal and non-small cell lung cancer. CRC Phase II Clinical Trials Committee. Br J Cancer. 1992 Apr;65(4):624-5. PubMed PMID: 1314072; PubMed Central PMCID: PMC1977569.

Additional Information